Dr. Choueiri highlights new adjuvant pembrolizumab findings in high-risk renal cell carcinoma
The new findings, “further support the use of adjuvant pembrolizumab after nephrectomy as a standard of care in patients with localized renal cell carcinoma at increased risk for recurrence,” says Toni K. Choueiri, MD.
In this video, Toni K. Choueiri, MD, discusses the findings from 2022 ASCO Annual Meeting abstract 4512: “Adjuvant pembrolizumab for postnephrectomy renal cell carcinoma (RCC): Expanded efficacy analyses from KEYNOTE-564.” The initial key findings from the trial showed that adjuvant pembrolizumab improved disease-free survival vs placebo in patients with RCC who are at high risk of recurrence. Choueiri explains that additional findings now show that the treatment also has significant benefits in terms of time to first subsequent drug treatment or any-cause death (TFST) and time from randomization to progression on next line of therapy or any-cause death (PFS2).
Choueiri is a professor of medicine at Harvard Medical School, and an attending physician, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
